LENZ Therapeutics Inc. (LENZ)
LENZ Therapeutics Statistics
Share Statistics
LENZ Therapeutics has 27.5M shares outstanding. The number of shares has increased by 230.56% in one year.
| Shares Outstanding | 27.5M |
| Shares Change (YoY) | 230.56% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 22.58M |
| Failed to Deliver (FTD) Shares | 1K |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 2.45M, so 8.92% of the outstanding shares have been sold short.
| Short Interest | 2.45M |
| Short % of Shares Out | 8.92% |
| Short % of Float | 10.97% |
| Short Ratio (days to cover) | 16.01 |
Valuation Ratios
The PE ratio is -0.81 and the forward PE ratio is -14.63. LENZ Therapeutics's PEG ratio is -0.04.
| PE Ratio | -0.81 |
| Forward PE | -14.63 |
| PS Ratio | 0 |
| Forward PS | 3 |
| PB Ratio | 0.55 |
| P/FCF Ratio | -1 |
| PEG Ratio | -0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for LENZ Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 39.2, with a Debt / Equity ratio of 0.
| Current Ratio | 39.2 |
| Quick Ratio | 39.2 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.2 |
| Cash Flow / Debt | -248.64 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | -0.68% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-20,775,166.67 |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -124.65M |
| Effective Tax Rate | 1 |
Stock Price Statistics
The stock price has increased by 36.79% in the last 52 weeks. The beta is 0.57, so LENZ Therapeutics's price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | 36.79% |
| 50-Day Moving Average | 25.86 |
| 200-Day Moving Average | 24.49 |
| Relative Strength Index (RSI) | 31.59 |
| Average Volume (20 Days) | 143.07K |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.41M |
| Operating Income | -73.11M |
| Net Income | -124.65M |
| EBITDA | -122.24M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -15.3 |
Balance Sheet
The company has 185.86M in cash and 362K in debt, giving a net cash position of 185.5M.
| Cash & Cash Equivalents | 185.86M |
| Total Debt | 362K |
| Net Cash | 185.5M |
| Retained Earnings | -367.05M |
| Total Assets | 224.01M |
| Working Capital | 212.99M |
Cash Flow
In the last 12 months, operating cash flow was -90.01M and capital expenditures -10.86M, giving a free cash flow of -100.86M.
| Operating Cash Flow | -90.01M |
| Capital Expenditures | -10.86M |
| Free Cash Flow | -100.86M |
| FCF Per Share | -12.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LENZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -71.2% |
| FCF Yield | -17.07% |
Analyst Forecast
The average price target for LENZ is $36, which is 67.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $36 |
| Price Target Difference | 67.5% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 22, 2024. It was a backward split with a ratio of 1:7.
| Last Split Date | Mar 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | 40.9 |
| Piotroski F-Score | 1 |